Point72 Asset Management
CERE

Point72 Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Point72 Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-111,400
Closed -$2.72M – 2915
2023
Q1 		$2.72M Sell
111,400
-291,729
-72% -$8.56M 0.01% 923
2022
Q4 		$12.7M Sell
403,129
-681,111
-63% -$19.2M 0.04% 471
2022
Q3 		$30.6M Buy
1,084,240
+881,940
+436% +$26.3M 0.12% 222
2022
Q2 		$5.35M Buy
+202,300
New +$5.74M 0.02% 685
2021
Q4 		– Sell
-141,400
Closed -$4.17M – 1360
2021
Q3 		$4.17M Sell
141,400
-227,150
-62% -$6.38M 0.02% 691
2021
Q2 		$9.44M Buy
368,550
+71,850
+24% +$1.03M 0.04% 463
2021
Q1 		$4.07M Buy
296,700
+176,700
+147% +$2.59M 0.02% 610
2020
Q4 		$1.99M Buy
+120,000
New +$1.56M 0.01% 731

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Point72 Asset Management's CERE Position: Q2 2023 in Review

Point72 Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2023, closing a stake of 111,400 shares — an estimated $2.72M sold.

Point72 Asset Management first reported a position in CERE in Q4 2020 and held it in 8 quarters. The position peaked at $30.6M in Q3 2022. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

  • Point72 Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Point72 Asset Management sold 111,400 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2023, an estimated $2.72M.
  • Point72 Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
  • Point72 Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $30.6M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.